Siponimod recommended for secondary progressive MS by EMA

The European Medicines Agency (EMA) has recommended that a licence should be granted for siponimod (Mayzent) for the treatment of active secondary progressive MS (SPMS).

Siponimod is taken as a tablet, once a day.

In clinical trials for secondary progressive MS, siponimod reduced the risk of disability progression by 21% compared to placebo. Further analysis indicated a 33% reduction in the risk of progression for those with active SPMS (defined as those who had relapsed in the two years prior to starting the trial).

More information can be found here.